Renaissance Technologies LLC Grows Position in Privia Health Group, Inc. $PRVA

Renaissance Technologies LLC boosted its position in Privia Health Group, Inc. (NASDAQ:PRVA) by 51.1% during the 1st quarter, Holdings Channel reports. The fund owned 776,500 shares of the company’s stock after acquiring an additional 262,500 shares during the quarter. Renaissance Technologies LLC’s holdings in Privia Health Group were worth $15,973,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue increased its position in shares of Privia Health Group by 1.3% in the 4th quarter. State of Alaska Department of Revenue now owns 65,747 shares of the company’s stock valued at $1,558,000 after purchasing an additional 823 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Privia Health Group by 8.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock worth $213,000 after purchasing an additional 840 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Privia Health Group by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock worth $535,000 after purchasing an additional 898 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Privia Health Group by 5.9% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock worth $385,000 after purchasing an additional 903 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its holdings in Privia Health Group by 456.2% in the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after buying an additional 926 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on PRVA shares. Weiss Ratings upgraded Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Barclays lowered their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 26th. Zacks Research downgraded Privia Health Group from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Canaccord Genuity Group cut their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Evercore set a $26.00 target price on Privia Health Group in a research note on Wednesday, April 8th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.15.

Privia Health Group Price Performance

NASDAQ PRVA opened at $23.67 on Friday. The firm’s fifty day moving average price is $24.51 and its 200 day moving average price is $23.35. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of 147.95, a price-to-earnings-growth ratio of 1.89 and a beta of 0.83. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $28.82.

Insider Activity at Privia Health Group

In other Privia Health Group news, Director Matthew Shawn Morris sold 53,722 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $27.24, for a total transaction of $1,463,387.28. Following the transaction, the director owned 68,188 shares of the company’s stock, valued at approximately $1,857,441.12. This trade represents a 44.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Mountcastle sold 21,275 shares of Privia Health Group stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $27.67, for a total value of $588,679.25. Following the sale, the chief financial officer owned 164,853 shares in the company, valued at $4,561,482.51. This trade represents a 11.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 454,580 shares of company stock valued at $11,492,189 over the last ninety days. Insiders own 5.70% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.